Deepak L. Bhatt

Deepak L. Bhatt is a US interventional cardiologist, researcher, and educator. He is known for novel clinical trials in cardiovascular prevention, intervention, and heart failure. As of 2024, he is the director of Mount Sinai Fuster Heart Hospital in New York City and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai Health System.^[1][2] Prior, he served as the executive director of Interventional Cardiovascular programs at Brigham and Women’s Hospital Heart and Vascular Center and a professor of medicine at Harvard Medical School.^[3][4] He was given the American College of Cardiology's Distinguished Mentor Award in 2018, and in 2019, the American Heart Association presented him with its Distinguished Scientist award.^[5] As of 2024, Google Scholar reports that he has been cited 294,036 times, has an h-index of 201, and an i10-index of 1,261.

Deepak L. Bhatt
Citizenship	United States
Alma mater	Massachusetts Institute of Technology, Cornell University, Harvard University, University of Oxford
Known for	Cardiovascular medicine, interventional cardiology
Scientific career
Fields	Clinical investigator, educator, author, cardiology
Institutions	Cleveland Clinic, VA Medical Center, Brigham and Women's Hospital, Harvard Medical School, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai
Website	https://deepakbhattmd.com/

Education and career

Bhatt graduated Boston Latin School, earned his science degree as a National Merit Scholar from MIT, an MD from Cornell and an MPH from Harvard.^[6] He received his Executive MBA from the University of Oxford in 2024.^[7]

He trained in internal medicine and cardiology at the University of Pennsylvania and Cleveland Clinic, completing fellowships in interventional cardiology and cerebral and peripheral vascular intervention. He served as chief interventional fellow at Cleveland Clinic^[8] where he worked as an interventional cardiologist, associate professor of medicine, director of the interventional cardiology fellowship, associate director of the cardiovascular medicine fellowship, and associate director of the cardiovascular coordinating center.^[9]

Later, he became the Chief of Cardiology at the VA Boston Healthcare System and, subsequently, the Interventional Cardiovascular Programs executive director at Brigham and Women’s Hospital. Additionally, he was a Senior Investigator in the TIMI Study Group and Editor-in-Chief of the Harvard Heart Letter.^[8] In 2012, he was appointed a professor of medicine at Harvard Medical School.^[10]

Board positions

As of 2024, Bhatt serves on the Board of Directors and Science and Technology Committee of Bristol Myers Squibb.^[11] He is on the cardiovascular advisory board for McKinsey and is a consultant to Broadview Ventures. He had previously served on the Board of Directors of the Boston VA Research Institute and as a Trustee of the American College of Cardiology.^[7] He serves on the Board of Directors of the American Heart Association New York City chapter.^[12]

Research

Focus

Bhatt focuses on several areas of cardiology, including interventional cardiology, heart attacks, stroke, prevention, and heart failure, as well as related areas such as high cholesterol, diabetes, and obesity.^[13] AD Scientific Index ranks him as one of the top 3% of scientists worldwide in his field.^[14]

Recent trials

Recent trials as of 2024 include:

Name, sponsor, role	Description
SOLOIST, Sanofi Lexicon, Chair[15]	Randomized controlled clinical trial (RCT) of sotagliflozin versus placebo in patients with diabetes and acute decompensated heart failure.
SCORED, Sanofi Lexicon, Chair[16]	RCT of sotagliflozin versus placebo in patients with diabetes and at high cardiovascular risk.
REDUCE-IT (Reduction of Cardiovascular Events with EPA – Intervention Trial), Amarin, Chair and PI.[17]	To determine definitively whether icosapent ethyl does or does not reduce cardiovascular risk in patients receiving intensive statin therapy.
CHAMPION PHOENIX, Chiesi, Co-Chair and Co-PI[18]	Industry-sponsored Phase 3 trial of cangrelor versus placebo in 11,000 patients undergoing percutaneous coronary intervention.
THEMIS, AstraZeneca, Co-Chair and Co-PI[19]	This is an international, multicenter, randomized trial of patients with diabetes and stable coronary artery disease randomized to the oral antiplatelet ticagrelor or to placebo on top of standard of care including aspirin.

Honors and awards

Brigham and Women’s Hospital chose Bhatt in 2014 as the Eugene Braunwald Scholar and in 2016 presented him with the Research Mentor Award, and in 2017 he was awarded the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology.^[6] He was given the American College of Cardiology’s Distinguished Mentor Award in 2018,^[20] and in 2019, the American Heart Association’s Distinguished Scientist Award.^[5][21] He received NLA’s Honorary Lifetime Membership Award in 2021, and the Society for Cardiovascular Angiography and Interventions’ Master Designation in 2022.^[2] Also in 2022, Research.com recognized him with its Best Scientists award.^[13] He was listed by the Web of Science Group as a Highly Cited Researcher from 2014 to 2024.^[12][22]

Publications

Books and book chapters

Bhatt is the Editor of the first and second editions of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease and of Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease.^[23] He is one of the co-editors of Braunwald’s Heart Disease.^[24] Elsevier credits him with a total of 11 titles as an author, chapter contributor, and editor.^[25]

Editorial

Bhatt was Senior Associate Editor for News and Clinical Trials for ACC.org, member of the Healio | Cardiology Today Editorial Board,^[26] and Editor-in-Chief of the Journal of Invasive Cardiology, which also lists him as:^[27]

• Former Editor-in-Chief, Harvard Heart Letter^[8]
• Former guest editor, Journal of the American College of Cardiology^[28]
• Former chief medical editor, Cardiology Today’s Intervention^[29]
• Deputy Editor, Clinical Cardiology.^[30]

Articles

As of 2024, Google Scholar reports that he has been cited 294,036 times, has an h-index of 201 and an i10-index of 1,261.^[31]

Bhatt has authored or co-authored over 2,000 publications^[32] and has been listed by the Web of Science Group as a highly cited researcher from 2014 to 2024.^{[33][34][35][22]}

Bhatt's most cited, peer-reviewed articles include:

• Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., Ruff, C. T., Gause-Nilsson, I. A. M., Fredriksson, M., Johansson, P. A., Langkilde, A. M., Sabatine, M. S., ... DECLARE–TIMI 58 Investigators (2019). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine, 380(4), 347–357. https://doi.org/10.1056/NEJMoa1812389 PMID 30415602 Cited by 5245^[36]
• Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., Cavender, M. A., Udell, J. A., Desai, N. R., Mosenzon, O., McGuire, D. K., Ray, K. K., Leiter, L. A., Raz, I., & SAVOR-TIMI 53 Steering Committee and Investigators (2013). Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England journal of medicine, 369(14), 1317–1326.^[37][38] Cited by 4135^[39]
• Adams, H. P., Jr, del Zoppo, G., Alberts, M. J., Bhatt, D. L., Brass, L., Furlan, A., Grubb, R. L., Higashida, R. T., Jauch, E. C., Kidwell, C., Lyden, P. D., Morgenstern, L. B., Qureshi, A. I., Rosenwasser, R. H., Scott, P. A., Wijdicks, E. F., American Heart Association, American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups (2007). Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke, 38(5), 1655–1711. PMID 17431204 Cited by 4072^[40][41]
• Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., Serebruany, V., Valgimigli, M., Vranckx, P., Taggart, D., Sabik, J. F., Cutlip, D. E., Krucoff, M. W., Ohman, E. M., Steg, P. G., & White, H. (2011). Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation, 123(23), 2736–2747. PMID 21670242 Cited by 4024^[42]
• Bhatt, D. L., Fox, K. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., Flather, M. D., Haffner, S. M., Hamm, C. W., Hankey, G. J., Johnston, S. C., Mak, K. H., Mas, J. L., Montalescot, G., Pearson, T. A., Steg, P. G., ... CHARISMA Investigators (2006). Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. The New England Journal of Medicine, 354(16), 1706–1717.^[43] Cited by 3790^[44]
• Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, PhD, Jiao L, Granowitz C, MD, PhD, Tardif JC, Ballantyne CM, for the REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.NEJM. 2019;380:11-22. PMID 30415628 Cited by 2003^[45]
• Bhatt DL, Kandzari DE, O’Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, for the SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. NEJM. 2014;370:1393-1401. PMID 24678939 Cited by 1643^[46]
• Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Díaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG; SCORED Investigators. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021 Jan 14;384(2):129-139. doi: 10.1056/NEJMoa2030186. Epub 2020 Nov 16. PMID 33200891 Cited by 1009^[47]